Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study
Carmen D. Herling, Kevin R. Coombes, Axel Benner, Johannes Bloehdorn, Lynn L. Barron, Zachary B. Abrams, Tadeusz Majewski, Jolanta E. Bondaruk, Jasmin Bahlo, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer, Bogdan A. Czerniak, Christopher C. Oakes, Alessandra Ferrajoli, Michael J. Keating, Lynne V. Abruzzo
Dive into the research topics of 'Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study'. Together they form a unique fingerprint.